| abstract |
Treatment of diseases and conditions using glucagon-like peptide-1 (GLP-1) and / or naturally or artificially generated mutants or analogs of GLP-1, or pharmaceutically acceptable salts thereof And / or providing methods and compositions related to the improvement. GLP-1 and / or naturally or artificially generated mutants or analogs of GLP-1 or pharmaceutically acceptable salts thereof are combined with one or more active agents (eg, D-Arg- A method and composition for the treatment and / or prevention of a disease or condition comprising administering in combination with an aromatic-cationic peptide such as 2'6'-Dmt-Lys-Phe-NH2. Furthermore, it contains one or more active agents, and the active agents are cyclosporine, cardiac medicine, anti-inflammatory. [Selection figure] None |